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Abstract
Background—To examine the performance of coronary artery calcification (CAC) for 
stratifying long-term risk of death in asymptomatic hypertensive patients.
Methods and Results—8905 consecutive asymptomatic individuals without cardiovascular 
disease or diabetes who underwent CAC testing (mean age 53.3±10.5, 59.3% male) were followed 
for a mean of 14 years and categorized on the background of hypertension (in accordance with the 
2014 Guidelines from the Joint National Committee 8) as well as age above or below 60 years. 
The prevalence and severity of CAC was higher for those with versus without hypertension 
(P<0.001), and the extent increased proportionally with advancing age (P<0.001). Following 
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adjustment, the presence of CAC in patients above and below the age of 60 years was associated 
with worse prognosis for hypertensive (HR 7.74 [95% CI: 5.15-11.63] and HR 3.18 [95% CI: 
2.42-4.19]) and normotensive (HR 4.83 [95% CI: 3.18-7.33] and HR 2.14 [95% CI: 1.61-2.85]), 
respectively. A zero CAC score was associated with a lower but persisting risk of mortality for 
hypertensives over the age of 60 years (HR 2.48 [95% CI: 1.50-4.08]); albeit, attenuating for those 
below the age of 60 years (P=0.09). In a “low risk” hypertensive population, a combined presence 
of hypertension and any CAC was associated with an almost five-fold (HR 4.68 [95% CI: 
2.22-9.87]) risk of death.
Conclusion—Among asymptomatic hypertensive individuals, the presence and extent of CAC 
effectively identified individuals at heightened risk of mortality beyond conventional 
cardiovascular risk.
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INTRODUCTION
One third of the adult population in the United States is affected by hypertension which 
remains a primary cause of mortality, accounting for approximately 14% of all US deaths.1 
Recently, the Joint National Committee set forth new guidelines regarding the clinical 
management of high blood pressure in adults.2 These guidelines diverge from prior 
recommendations, with an age-stratified difference in recommendation for targeted blood 
pressure goals. Specifically, in hypertensive subjects younger than 60 years free from 
diabetes and kidney disease, these guidelines further state that the management of blood 
pressure should be determined based upon of clinical evaluation and use of the global 
cardiovascular risk assessment scores.
To this end, novel tools that effectively stratify risk of younger and older individuals with 
hypertension are needed.3,4 In short- and intermediate-term follow-up, the assessment of 
coronary artery calcification (CAC) scoring by computed tomography (CT) imaging is a 
non-invasive tool that enables accurate stratification of risk.5-9 Specifically, the 
presence,10,11 severity,12 and progression13,14 of CAC has been shown to be independently 
associated with major adverse cardiovascular events10-15 and death,6,10,15-21 while a low 
risk of adverse outcomes has been observed in the absence of CAC.22-24 Nevertheless, these 
investigations lack insight towards the long-term efficacy of CAC for risk stratification, are 
limited in their focus among the hypertensive population, and have not yet examined the 
prognostic utility of CAC for hypertensive individuals when stratified by age.
To address this, in a large consecutive cohort of asymptomatic hypertensive individuals 
followed for 14 years, we sought to examine whether CAC could accurately stratify the risk 
of mortality
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METHODS
Study population
The study cohort comprised 9715 consecutive asymptomatic individuals (41% female) 
without known coronary artery disease (CAD). All individuals referred by their physicians 
for electron beam computed tomography (EBCT) underwent CAC testing from a single site. 
Of 9715 individuals, 810 were excluded due to the presence of type 2 diabetes. The 
remaining 8905 individuals (mean age 53.3±10.5, 59.3% male) who represented the study 
population were divided into 2 groups based on hypertension status (Table 1). From the 
remaining cohort, we identified a sub-population of individuals without other traditional 
cardiovascular risk factors, as defined by the absence of dyslipidemia, family history of 
premature CAD, and smoking status (n=781). Those individuals are considered by 
definition,22 at low Framingham risk score (FRS) risk (herein referred to as low-risk 
subgroup). All screened individuals provided informed consent to undergo EBCT and the 
study received approval from the appropriate Human Investigations Committee.
Risk factor collection
All study participants were prospectively provided with a questionnaire for the collection of 
demographic characteristics as well as baseline cardiovascular risk factors. The following 
risk factors were considered in this study: 1) cigarette smoking was present if a subject was 
an active smoker at the time of scanning; 2) dyslipidemia was considered to be present for 
any individual reporting a history of high total cholesterol, high low density lipoprotein 
cholesterol, low high-density lipoprotein cholesterol, high triglycerides, or current use of 
lipid-lowering therapy; 3) diabetes was defined as baseline use of anti-diabetic medication 
or had a history of elevated blood glucose measurement of >126 mg/dl; 4) hypertension was 
defined as a self-reported history of high blood pressure or use of antihypertensive 
medication; and 5) family history of premature CAD was determined by asking individuals 
whether any member of their immediate family (parents or siblings) had a history of fatal or 
nonfatal myocardial infarction and/or coronary revascularization in a male relative <55 years 
or a female relative <65 years.
EBCT screening protocol
All subjects underwent EBCT on either a C-100 or C-150 Ultrafast CT scanner (GE-
Imatron, South San Francisco, California). With a tomographic slice thickness of 3 mm, a 
total of approximately 40 sections were obtained beginning at the level of the carina and 
proceeding caudally to the level of the diaphragm. Images were obtained with a 100-ms/
slice scanning time, with image acquisition electrocardiographically triggered at 60% to 
80% of the R-R interval. A calcified lesion was defined as >3 contiguous pixels with a peak 
attenuation of at least 130 Hounsfield units. Each lesion was then scored using the method 
developed by Agatston et al.25 (Agatston units).
Study outcome
The primary endpoint of this study was death from all-causes. Ascertainment of mortality 
status was conducted by individuals masked to baseline historical data and EBCT results, 
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and was verified using the Social Security Death Index. The Social Security Death Index is a 
national registry of all deaths that have occurred in the United States, allowing for 100% 
mortality ascertainment among study participants.
Statistical methods
Categorical variables are presented as counts with proportions (%) and continuous variables 
as mean±SD or median and interquartile range. The chi-square test was employed for 
comparison of categorical variables. Between-group comparisons for continuous variables 
were computed using the independent samples t-test or the Mann-Whitney U test as 
appropriate. A Kaplan-Meier survival curve with log-rank test was employed to compare 
survival rates for hypertensives versus normotensives above or below the age of 60 years, 
according to existing or absent CAC. Cox proportional hazard regression reporting hazard 
ratios (HR) with 95% confidence intervals (95% CI) were performed to examine the risk of 
death from all causes in the overall study population. Separately, we repeated the Cox 
analyses for the low-risk sub-group (i.e., with no traditional cardiovascular risk factors). All 
Cox models were stratified according to hypertension status, age above and below 60 years, 
and the presence or absence, as well as severity of CAC. Additionally, all Cox models 
adjusted for gender, smoking, dyslipidemia, and family history of premature CAD. We 
additionally tested the incremental prognostic value of CAC over and above an established 
risk algorithm, the Framingham Risk Score (FRS), using the area under the receiver operator 
characteristic curve (AUC). Further, we computed the net reclassification improvement 
(NRI),26 which provides an estimate in percentage gain in reclassification for a pre-specified 
set of cut-off points. For the latter analysis, we chose risk categories based on low (<10%), 
intermediate (10% to 20%), and high (>20%) 10-year Framingham risk.27 Statistical 
analyses were performed using SAS version 9.3 software (SAS Institute Inc., Cary, NC). A 
two-tailed P value <0.05 was considered statistically significant.
RESULTS
Study population
Demographic characteristics of the study cohort are summarized in Table 1. The mean 
follow-up was 14.6±1.0 years. There were 748 (8.4%) deaths in the study population; 408 
(11.0%) occurred in hypertensive individuals with the remaining 340 (6.6%) deaths 
occurring in normotensive subjects. Overall, age, prevalent dyslipidemia, smoking status 
and family history of premature CAD, as well as CAC score ranged from 0- 8876 in 8905 
patients. 4589 patients (51.5%) had a CAC score of zero and 4316 (48.5%) had non-zero 
CAC score, with a median score of 0 (interquartile range [IQR]: 0-60).
Distribution of CAC
Figure 1 describes the distribution of CAC severity according to individuals stratified by 
hypertension and age. The prevalence of zero CAC was greater among individuals without 
hypertension. Notably, the severity of CAC increased significantly on the background of 
hypertension and age (P<0.001).
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CAC and all-cause mortality
Figure 2 reports the impact of CAC on mortality according to individuals stratified by 
hypertension and age. Incident mortality was lowest in normotensive individuals aged below 
60 years without the presence of CAC, and highest for hypertensive individuals aged above 
60 years. For individuals below the age of 60 years, there was no significant difference in 
the incidence of mortality for those with and without hypertension when the CAC was zero. 
Kaplan-Meier survival curves are reported in Figure 3. Irrespective of hypertension status 
and age, the presence of CAC was associated with worse prognosis (Figure A and B, both 
P<0.001). Of note, in hypertensive subjects, the absence of CAC was associated with a 
higher cumulative survival for individuals above 60 years old compared with individuals 
presenting with CAC (Figure 3 A). Moreover, among hypertensive subjects below 60 years 
old, cumulative survival was similar when compared with individuals without hypertension 
and CAC (Figure 3 B). In multivariable Cox analyses (Figure 4), the combined presence of 
CAC and hypertension was associated with the greatest risk of mortality, owing to an almost 
8-fold (95% CI: 5.15-11.63) and greater than 3-fold (95% CI: 2.42-4.19) adjusted risk of 
mortality in individuals above and below the age of 60 years, respectively. In hypertensive 
individuals, the risk of death appeared to increase incrementally according to the severity of 
CAC – in older hypertensive subjects a CAC score above 100 was associated with the 
greatest risk of mortality owing to a more than 10-fold (HR 10.97; 95% CI 7.23-16.64) 
increase in the risk (Table 2). In contrast, in the absence of CAC, hypertension alone was 
associated with a lower, albeit significant heightened risk of mortality in those above the age 
of 60 years (HR 2.48; 95% CI 1.50-4.08); the association between hypertension and 
mortality was not significantly elevated among individuals below the age of 60 years (HR 
1.35; 95% CI 0.95-1.91; P=0.09).
Utility of CAC for individuals without additional cardiovascular risk factors
We further investigated the utility of CAC for predicting the risk of mortality in a population 
of subjects without cardiac risk factors other than hypertension (n=781). CAC was present in 
53% and 34% of individuals with and without hypertension, respectively. Cox proportional 
hazard regression analyses adjusting for age and gender indicated the presence of 
hypertension alone was not associated with an increased risk of mortality when CAC was 
absent (Figure 4). However, the combined presence of hypertension and CAC conferred an 
almost 5-fold adjusted risk of death in these apparently “low-risk” individuals. Albeit, this 
observed increased risk in mortality appeared to be independent on CAC severity (Table 3).
Discrimination and reclassification
Compared with the FRS alone, discrimination improved significantly (AUC [Area under the 
receiver operating characteristics curve] 0.71 versus 0.62; p < 0.001) when CAC was added 
to the FRS (Figure 5). The addition of CAC to the FRS further resulted in a 37% and 13% 
correct reclassification of individuals to a different risk category that defined the experience 
or no experience of an event, respectively (P<0.001). The net NRI was actually 23.3%.
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DISCUSSION
In the present study, we found CAC to be an efficacious tool for long-term identification and 
exclusion of individuals with hypertension who are at heightened risk of mortality. Our 
study highlights three main findings. First, in hypertensive individuals aged above 60 years, 
death from all-causes dramatically increased in proportion to the severity of CAC. Second, 
among younger adults (i.e., below the age of 60 years), the effect of the presence of CAC 
was considerably less pronounced – importantly the absence of CAC was associated with an 
excellent long-term survival even in presence of hypertension, beyond other conventional 
risk factors. Third, in a selected “low risk” population the presence of CAC considerably 
increased the risk of death while correctly reclassifying individuals from low-to-
intermediate into a higher risk category.
These findings emphasize the use of a risk marker such as CAC as additive to conventional 
risk factors for identifying patient-specific risk of future adverse cardiovascular events. 
While the utility of CAC in the management of hypertensive individuals was not accounted 
for by the JNC 8 guidelines, based on the current study findings, CAC evaluation may assist 
in driving the diagnostic and therapeutic management of this category of individuals. CAC 
has the potential to identify a heightened at-risk group of hypertensive individuals greater 
than 60 years who may require blood pressure lowering even further below the current 
guidelines of 150/90 mmHg. Moreover, even among asymptomatic hypertensive individuals 
with no additional traditional cardiovascular risk factors, the presence and severity of CAC 
was effective in identifying increased risk of death. This ostensibly “low risk” population 
may easily be overlooked by traditional risk factor scoring, and yet the prevalence of CAC 
was common in this cohort. On the other hand, in hypertensive subjects below the age of 60 
years, the absence of CAC demonstrated excellent long-term prognosis suggesting those 
individuals might benefit from milder treatment, with higher therapeutic targets 
supplemented by lifestyle modifications and fewer clinical re-evaluations.
Whether CAC can be used to further guide patient-specific therapies beyond conventional 
cardiovascular risk alone is beyond the scope of this study, but nevertheless, evokes the 
possibility that a CAC-guided approach to treatment may improve future clinical outcomes. 
Studies examining this hypothesis now appear warranted.
Importantly, the present study findings are directly additive to the current body of evidence 
that has examined the use of CAC in the asymptomatic hypertension population20,28. First, 
we followed all individuals with hypertension—irrespective of their level of risk—for nearly 
15 years. Prior studies have focused primarily upon intermediate-risk patients, with very few 
event analyses performed for low-risk individuals (e.g., 1 or 2 clinical events).29,30 In 
contrast, given our study sample size and duration of follow-up, we observed a substantially 
elevated risk of mortality even amongst individuals considered low-risk by the FRS but with 
present CAC. Finally, the inclusion of CAC demonstrated significantly improved risk 
stratification and discrimination above and beyond the FRS, underlining the high prognostic 
utility of this clinical parameter in an asymptomatic hypertension population.
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This study is not without limitations. First, we employed all-cause mortality as a primary 
endpoint in this study, given its freedom from ascertainment and knowledge bias. However, 
it remains likely that coronary-specific deaths that occurred for individuals within this study 
were diluted from deaths from other causes.31 Importantly, however, this relative dilution 
likely contributed to an under-, rather than over-estimation, of the effect of the current study 
findings. Second, the effects of CAC scoring on incident changes to medical therapy and/or 
lifestyle modification are not known in this study, and their mitigating effects to reduce (or 
increase) mortality rates is unknown. Third, the self-reporting of risk factors, in particular 
diabetes, beyond current established guidelines should be considered another limitation of 
this investigation - though prior studies have demonstrated the reliability of self-reporting 
cardiovascular risk factors.32 Finally, despite the large study sample, long-term follow-up 
and prospective evaluation of study individuals, the single-center nature of the present study 
may nevertheless be associated with a reduced generalizability in lieu of multicenter studies. 
On the whole, individuals were enrolled based on a referral for EBCT – therefore, the 
current study individuals could be deemed to be somewhat at higher risk, which could have 
influenced the general applicability of our findings to other apparently healthy populations.
In conclusion, in a long-term follow-up of nearly 15 years, the presence and severity of CAC 
effectively prognosticates future mortality for asymptomatic hypertensive individuals, which 
were more pronounced in subjects greater than 60 years. On the other hand, the absence of 
CAC in hypertensive individuals aged below 60 years confers a 15-year survival similar to 
non-hypertensive subjects. This study advocates the possibility that a CAC-driven approach 
to treatment may improve clinical outcomes in the future. Prospective studies examining this 
hypothesis now appear necessary.
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Figure 1. 
Severity of coronary artery calcification among hypertensive and non-hypertensive 
individuals stratified by age above and below 60 years.
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Figure 2. 
Annual mortality rate according to hypertension and coronary artery calcification in 
individuals above and below the age of 60 years
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Figure 3. 
Kaplan-Meier survival curves for all-cause mortality according to categories of hypertension 
and coronary artery calcification in individuals above (a) and below (b) the age of 60 years
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Figure 4. 
Risk of all-cause mortality among individuals stratified by hypertension and coronary artery 
calcification for those above and below the age of 60 years, as well as without additional 
cardiac risk factors (low-risk category). Hazard ratios with 95% confidence intervals are 
reported. Models adjusted for gender, smoking, dyslipidemia, and family history of 
premature coronary artery disease. Low-risk category was adjusted for just age and gender.
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Figure 5. 
Discrimination for all-cause mortality according to the area under the receiver operating 
characteristic curve (ROC) using the coronary artery calcium score. Model A represents the 
Framingham Risk Score (base model). Model B included the base model as well as log 
coronary artery calcium score.
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Table 2
15-year survival stratified by hypertension status and coronary artery calcium score in individuals above and 
below 60 years.
Unadjusted HR Adjusted HR*
HR (95% CI) p-Value HR (95% CI) p-Value
Age≥60
No Hypertension
CAC 0 1.00 (ref) 1.00 (ref)
CAC 1-99 3.36 (2.10-5.39) <0.001 3.47 (2.16-5.57) <0.001
CAC >100 6.34 (4.08-9.87) <0.001 6.58 (4.22-10.25) <0.001
Hypertension
CAC 0 2.15 (1.31-3.53) 0.003 2.45 (1.49-4.05) <0.001
CAC 1-99 3.62 (2.24-5.85) <0.001 4.17 (2.57-6.77) <0.001
CAC ≥100 10.21 (6.75-15.43) <0.001 10.97 (7.23-16.64) <0.001
Age<60
No Hypertension
CAC 0 1.00 (ref) 1.00 (ref)
CAC 1-99 1.87 (1.34-2.60) <0.001 1.79 (1.28-2.49) 0.001
CAC ≥100 3.05 (2.16-4.30) <0.001 2.80 (1.98-3.96) <0.001
Hypertension
CAC 0 1.29 (0.91-1.82) 0.15 1.35 (0.95-1.91) 0.09
CAC 1-99 2.79 (2.04-3.82) <0.001 2.75 (2.00-3.77) <0.001
CAC ≥100 4.24 (3.10-5.81) <0.001 3.85 (2.79-5.30) <0.001
*Adjusted for gender, smoking, dyslipidemia, and family history of premature coronary artery disease.
HR hazard ratio; 95% confidence interval; CAC Coronary artery calcium score.
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Table 3
15-year survival stratified by hypertension status and coronary artery calcium in the “low risk” population
Unadjusted HR Adjusted HR*
HR (95% CI) p-Value HR (95% CI) p-Value
No Hypertension
CAC 0 1.00 (ref) 1.00 (ref)
CAC 1-99 2.04 (0.82-5.07) 0.13 1.80 (0.72-4.50) 0.21
CAC ≥100 10.63 (4.98-22.71) <0.001 6.97 (3.22-15.09) <0.001
Hypertension
CAC 0 1.17 (0.37-3.67) 0.79 1.13 (0.36-3.55) 0.84
CAC 1-99 5.16 (2.24-11.91) <0.001 5.00 (2.16-11.54) <0.001
CAC ≥100 5.93 (2.39-14.76) <0.001 4.34 (1.73-10.89) 0.002
*Adjusted for age and gender.
HR hazard ratio
CAC Coronary artery calcium score
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